Anti-Angiogenic Peptide

Description:

Anti-Angiogenic Peptide

NJIT Case No. 18-029

 

Inventors: Vivek A. Kumar, Peter K. Nguyen, Biplab Sarkar, Sruti Rachapudi, Patricia Iglesias-Montoro

Intellectual Property & Development status: Patent protection is pending.

NJIT is currently seeking commercial partners for the further development and commercialization of this opportunity.

 

Technology Brief: Researchers at the New Jersey Institute of Technology in the Departments of Biomedical Engineering have invented a novel, noninvasive, and cost-effective therapy for neovascular diseases.

Pathological neovascularization of tissues can lead to a host of diseases. Diabetic Retinopathy (DR) and wet Macular Degeneration (WMD) are intraocular posterior segment diseases that are caused by formation of aberrant blood vessels in the retina and the choroid. Current treatments for these diseases include frequent injections of anti-angiogenic monoclonal antibodies into the vitreous humor and/or invasive surgical procedures. The invention is a safe and cost-effective therapy that leads to long-term attenuation of aberrant neovascularization. The self-assembling peptide hydrogel (SAPH) is biodegradable, biocompatible and injectable. The hydrogel intrinsically inhibits angiogenesis in neovascular diseases over months-long periods. Additionally, SAPH has potential application in drug delivery, wound healing, and inhibition of tumor angiogenesis.

 

Advantages       

•       Injectable

•       Cost-effective

•       Biocompatible and biodegradable

•       Non-toxic

•       Prolonged effect

•       Increased specificity

 

Applications       

•       Neovascular diseases

o       Diabetic retinopathy

o       Macular degeneration

•       Tumor regression

•       Drug delivery

•       Would healing

•       Tissue engineering

 

Inventor’s Bio: Vivek Kumar is an assistant professor in the Departments of Biomedical Engineering, and Chemical & Materials Engineering at the New Jersey Institute of Technology. Before that, he was a NIH F32 postdoctoral fellow at Rice University and BIDMC, Harvard Medical School. He completed his Ph.D. in Bioengineering at the Georgia Institute of Technology under the supervision of world-renowned surgeon-scientist Elliot Chaikof, MD, PhD. He received his BSc in Biomedical Engineering from Northwestern University. Dr. Kumar’s research focus is the development of biomaterials and composites for a variety of tissue engineering applications including, drug delivery, regenerative medicine, therapeutic angiogenesis, and inflammation modulation. Materials developed in the KumarLab (kumarlab.njit.edu) are being explored for treatment of a variety of indications including cholesterol lowering (PCSK-9) inhibitors, novel hemostats, chemotherapeutic delivery, treatment of aberrant vasculature in diabetic retinopathy, stem cell delivery, vaccine adjuvants, microbicides, neurogenic peptides for neuroprotection and regeneration after stroke/ TBI, dental pulp regeneration, and tissue engineered blood vessels. Dr. Kumar is a prolific author with over 14 years of experience in the synthesis, characterization and translation of a range of biomaterials with over 30 peer-reviewed research articles, over 30 conference presentations/abstracts, 8 issued/pending patents, and 2 University technology driven start-ups. His publications have been cited nearly 1000 times, with a h-index of 17. Dr. Kumar has received multiple awards for both his academic and entrepreneurial work — including the Ruth L. Kirschstein National Research Service F32 Award, American Heart Association Predoctoral Fellowship, & numerous awards at scientific meetings and pitch events.

 

 

Patent Information:
Category(s):
Diagnosis/Therapeutics
For Information, Contact:
Simon Nynens
VP, Business Incubation
New Jersey Institute of Technology
simon.nynens@njit.edu
Inventors:
Vivek Kumar
Peter Nguyen
Biplab Sarkar
Sruti Rachapudi
Patricia Iglesias-Montoro
Keywords:
Patent Pending
© 2019. All Rights Reserved. Powered by Inteum